EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice

EMAEMA, in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC), has launched the Cancer Medicines Forum (CMF). Bringing together representatives from academic organisations and the European medicines regulatory network, the forum aims at advancing research into optimising cancer treatments and will contribute to foster high standards in cancer care in the European Union (EU).

Since its establishment in 1995, EMA has reviewed and recommended for approval over 170 cancer medicines that have gone on to play an important role in the treatment and management of various types of cancers. The field of oncology has seen the emergence of major innovations in recent years, including the arrival of personalised medicines, immunotherapies, and advanced therapy medicinal products. Such innovations have helped cancer patients across Europe by offering them new tools in their fight against the disease. However, at the time new medicines enter the market, there is an opportunity to improve many aspects with respect to their optimal use and integration into the existing array of treatments. Addressing these opportunities for treatment optimisation may require the conduct of studies to collect robust data to further guide clinical practice.

The Cancer Medicines Forum has met today for the first time to discuss challenges around the research into optimisation of treatments, such as dose-optimisation and similar approaches tailored to the characteristics of the patient and the disease. Meetings will be organised quarterly, including representatives of key academic organisations from EMA's Healthcare Professionals Working Party. The results of these discussions will support the prioritisation of actions to fight cancer included in the Regulatory Science Strategy to 2025 and the Academia Collaboration Matrix Action Plan. Following a one-year pilot phase, the composition and working procedures of the forum will be re-evaluated.

Further information about the Cancer Medicines Forum will be published on EMA's academia webpage.

Most Popular Now

AstraZeneca enters license agreement with KYM Bios…

AstraZeneca and KYM Biosciences Inc.* have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targetin...

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

AI conjures proteins that speed up chemical reacti…

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in...